RAPT rapt.com: Price-to-Projected Revenue Ratio
RAPT Therapeutics, Inc. (RAPT) focuses on developing safe oral therapies for cancer and inflammation. The forward P/S ratio demonstrates market confidence in these developments, with the 810.70 mark characterizing this parameter. Business resilience depends on the lifting of FDA regulatory restrictions and the efficacy of immuno-oncology. A strong patent portfolio and the complexity of molecular synthesis create a robust defensive barrier against competitors.
Analytical breakdowns for RAPT Therapeutics, Inc. (RAPT)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Equity Ratio RAPT Therapeutics, Inc.|RAPT - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio RAPT Therapeutics|RAPT - Aggregate Debt Obligations|Debt to Book Value RAPT Therapeutics, Inc.|RAPT - Amount of Long-Term Liabilities|Company Short-Term Debts RAPT Therapeutics|Quick Ratio rapt.com
- financial results and valuation multiples details:
RAPT - Company Net Income|Expected Profit RAPT Therapeutics, Inc.|RAPT - Company Value to Net Income|Forward P/E Multiple rapt.com|RAPT - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization RAPT Therapeutics|RAPT - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) RAPT Therapeutics|RAPT - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months rapt.com|RAPT - Earnings growth in current year|Expected earnings per share growth for next year RAPT Therapeutics, Inc.
- total revenue and sales volume data:
Summary company analysis:RAPT Therapeutics, Inc. (RAPT)
It is critical for investors to determine asset stability by comparing market capitalization with projected revenue to filter out speculative risks. The current value of 810.70 reflects the balance between market expectations and the technological reliability of the California-based laboratories of RAPT Therapeutics, Inc. (RAPT), where capacity redundancy reduces operational disruptions, although the high volatility of the forward P/S trajectory indicates significant price sensitivity to any changes in sales forecasts.
Competing companies
Forward P/S Multiple ARGX (argenx.com)|BioNTech Group (BNTX) - Market Cap to Future Revenue Ratio|ABIVAX - Forward P/S Multiple|ADMA - Forward P/S Multiple|Protagonist (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Immunovant Inc|Price-to-Projected Revenue Ratio Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|Price-to-Projected Revenue Ratio CLDX (Celldex Therapeutics)|Price-to-Projected Revenue Ratio Aurinia Pharma AUPH|Forward Price to Sales BCRX|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Forward P/S Multiple|Market Cap to Projected Revenue PGEN (Intrexon)|Forward Price-to-Revenue Multiple PHAR (Pharming)|NKTR (Nektar) - Forward Price to Sales|Forward P/S Multiple UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Future Price to Revenue|IMNM - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Gossamer Bio Inc GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna Pharma|PVLA (Pieris Corp) - Forward P/S Multiple|Price-to-Projected Revenue Ratio SVRA|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple AnaptysBio Corp ANAB|Astria Therapeutics Inc - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc. (ENGN)|Aerovate - Forward P/S Multiple|ACRS - Forward P/S Multiple|KYTX (Kyverna Therapeutics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Tiziana Life Sciences Ltd. (TLSA)|Forward Price-to-Revenue Multiple CABA|Ventyx Biosciences (VTYX) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics, Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (eledon.com)|AGEN - Forward Price-to-Revenue Multiple|CLYM - Price-to-Projected Revenue Ratio|Future Price to Revenue ZURA|ATYR: Forward P/S Multiple|Adagene Corp (ADAG) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IMA|Shattuck Labs, Inc. - Future Price to Revenue|Price-to-Projected Revenue Ratio Equillium Inc (EQ)|Forward P/S Multiple Connect Biopharma Holdings (CNTB)|Price-to-Projected Revenue Ratio Immunic, Inc. IMUX|Forward P/S Multiple Atara Biotherapeutics ATRA|IFRX - Price-to-Projected Revenue Ratio|XFOR: Price-to-Projected Revenue Ratio|ACET: Forward P/S Multiple|CELU - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio inmunebio.com|Market Cap to Projected Revenue BRNS (barinthusbio.com)|Forward P/S Multiple KZR|Forward P/S Multiple SAB Biotherapeutics, Inc (SABS)|Forward P/S Multiple AKTX (Akari Therapeutics, Plc)|Forward P/S Multiple enlivex.com ENLV|QTTB: Forward Price-to-Revenue Multiple|GOVX - Forward P/S Multiple|Edesa Biotech Inc (EDSA) - Price-to-Projected Revenue Ratio|IBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio carismatx.com|XTLB: Forward Price to Sales|Price-to-Projected Revenue Ratio Bolt Biotherapeutics Inc. (BOLT)|HCW Biologics - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio aptevotherapeutics.com APVO|AIM - Forward Price-to-Revenue Multiple|Aditxt - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Corporation GRI|xortx.com (XRTX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reshapelifesciences.com (HIND)|Price-to-Projected Revenue Ratio Revelation Bio|Market Cap to Future Revenue Ratio Indaptus Therapeutics, Inc. INDP|Price-to-Projected Revenue Ratio BiondVax Pharmaceuticals (SCNI)|Forward Price-to-Revenue Multiple CalciMedica CALI|Price-to-Projected Revenue Ratio Affimed AFMD|ALLK - Forward Price-to-Revenue Multiple|HOOKIPA Pharma, Inc. - Forward P/S Multiple|Forward Price to Sales IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Ocean Biomedical Corp (OCEA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Forward P/S Multiple thirdharmonicbio.com
